Fda approval · on the rundown Thursday, July 16, 2026
FDA approves once-daily oral PCSK9 inhibitor Lipfendra, Merck says
Covered by 8 outlets over 4 hours. They ran 3 distinct reports; the most widely run, a syndicated copy, appeared on 5 sites. First reported by iHeartRadio at 17:00 UTC on July 16, 2026.
- outlets8
- distinct reports3
- first to latest report4 h
- names in it2
What happened?
- Merck announced the FDA approved Lipfendra (enlicitide), described as the first once-daily oral PCSK9 inhibitor.
- Merck's announcement said that, across 24 weeks, Lipfendra reduced LDL cholesterol by almost 60 percent versus placebo.
- The reports state that Lipfendra will be available, with a list price of $315 each month.
The U.S. Food and Drug Administration approved Lipfendra (enlicitide), a once-daily oral PCSK9 inhibitor, Merck announced Thursday. According to Merck's announcement, the tablet is approved for adults with hypercholesterolemia, including inherited forms, as an add-on to diet and other cholesterol-lowering therapies.
A machine summary written from the reports listed below; read them for the full account. How summaries are made and what is checked.
Who reported it, and when?
| Time | Report | Run by |
|---|---|---|
| Jul 16 17:00 | Report by iHeartRadio |
|
| Jul 16 21:00 | Report by mynbc5.com | |
| Jul 16 21:00 | Report by record-bee.com |
A report's title is shown once our automated legal check has read it and passed it; these reports are named by outlet, and the links lead to each report.
Who was named?
More news naming Food and Drug Administration
- Oct 1 · Healthcare Three states ask Supreme Court to review abortion shield laws 2
- Oct 1 · Biotech Court upholds patent claims in United Therapeutics-Liquidia dispute 2
- Oct 1 · Biotech OS Therapies Adds 2 Execs to Drive 3-Market Herlystic Launch 2
- Sep 29 · Biotech Unicycive resubmits NDA for oxylanthanum carbonate 2
- Sep 29 · Healthcare RefluxStop U.S. Launch Draws 120+ Surgeons at AFS 2026 2
- Sep 25 · Biotech nbcconnecticut.com: “FDA nominee says vaccines are safe” 2
- Sep 24 · Biotech FDA panel backs Grail's multi-cancer blood test 2
- Sep 22 · Biotech GLP-1 drugmakers face lawsuits over alleged sudden vision loss risk 4
Sources: the outlets' reports linked on this page; counts and times from GetYourBrief's record of those reports (methodology).